You are here
CERID Bibliography
Export 31 results:
Author Title [ Type] Year Filters: Keyword is Animals and Author is Gelb, Michael H [Clear All Filters]
2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials. Bioorg Med Chem Lett. 2008 ;18(2):494-7.
. 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. J Med Chem. 2008 ;51(3):384-7.
. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci U S A. 2003 ;100(25):15149-53.
. C-terminal proteolysis of prenylated proteins in trypanosomatids and RNA interference of enzymes required for the post-translational processing pathway of farnesylated proteins. Mol Biochem Parasitol. 2007 ;153(2):115-24.
. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. J Med Chem. 2004 ;47(2):432-45.
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother. 2007 ;51(10):3659-71.
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother. 2008 ;52(10):3710-7.
Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol. 2006 ;148(2):144-60.
In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg Med Chem. 2004 ;12(24):6517-26.
Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents. Bioorg Med Chem Lett. 2009 ;19(23):6582-4.
. Isothiazole dioxides: synthesis and inhibition of Trypanosoma brucei protein farnesyltransferase. Bioorg Med Chem Lett. 2002 ;12(16):2217-20.
. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother. 2012 ;56(9):4914-21.
Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. J Med Chem. 2008 ;51(17):5176-97.
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol. 2003 ;126(2):155-63.
. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr Opin Investig Drugs. 2005 ;6(8):791-7.
. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem. 2005 ;48(17):5415-8.
. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 ;48(11):3704-13.
Protein geranylgeranyltransferase-I of Trypanosoma cruzi. Mol Biochem Parasitol. 2008 ;157(1):32-43.
. Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem. 2009 ;52(6):1639-47.
. Regulation and function of epithelial secreted phospholipase A2 group X in asthma. Am J Respir Crit Care Med. 2013 ;188(1):42-50.
Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol Biochem Parasitol. 2007 ;152(1):66-71.
. Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem. 2005 ;280(14):13554-9.
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem. 2010 ;53(10):3887-98.
. Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem. 2007 ;50(19):4585-605.